Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1996-10-28
|
pubmed:abstractText |
Minimal inhibitory concentrations (MICs) of sparfloxacin (SFX) were determined by agar dilution for 3,164 bacterial strains isolated in 10 university hospitals; in addition, antibiograms by agar diffusion were performed with 5 micrograms disks. Activity of SFX against nalidixic acid (NAL) susceptible (S) Enterobacteriaceae was close to that of other fluoroquinolones (FQ) (MIC 50 and 90: 0.06-0.5 microgram/ml); like for other FQ, this activity was reduced against NAL intermediate and resistant (R) Enterobacteriaceae (2-16). MICs of SFX against P. aeruginosa were between 0.12 and 16 (1-32). SFX had also a good activity against NAL-S A. baumannii (CMI < or = 0.25) but this activity is reduced against NAL-R Acinetobacter (16). SFX was highly active against Haemophilus (0.016-0.06) gonococci (0.008), meningococci (0.008) and B. catarrhalis (0.008-0.03). SFX showed activity superior to the currently available FQ against methicillin susceptible staphylococci (0.06); the resistant strains [8] are usually methicillin resistant. SFX is more effective against enterococci (0.5), streptococci (0.25-0.5) and particularly pneumococci (0.25-0.5) including penicillin-resistant strains. The coefficient correlation of the regression curve is 0.876; for MIC breakpoints of 1 and 2 micrograms/ml, zone diameter breakpoints should be 20 and 16 mm.
|
pubmed:language |
fre
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0369-8114
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
241-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8763585-Anti-Infective Agents,
pubmed-meshheading:8763585-Bacteria, Anaerobic,
pubmed-meshheading:8763585-Cross Infection,
pubmed-meshheading:8763585-Enterobacteriaceae,
pubmed-meshheading:8763585-Escherichia coli,
pubmed-meshheading:8763585-Fluoroquinolones,
pubmed-meshheading:8763585-Gram-Negative Bacteria,
pubmed-meshheading:8763585-Gram-Positive Bacteria,
pubmed-meshheading:8763585-Humans,
pubmed-meshheading:8763585-Quinolones,
pubmed-meshheading:8763585-Regression Analysis
|
pubmed:year |
1996
|
pubmed:articleTitle |
[In vitro antibacterial activity of a new fluoroquinolone, sparfloxacin, against nosocomial bacteria, and concordance curve].
|
pubmed:affiliation |
Service de Bactériologie, CHU Henri-Mondor, Créteil, France.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
In Vitro,
English Abstract,
Multicenter Study
|